{"id":"NCT01747629","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics","officialTitle":"A 12-week Comparison of the Efficacy and Safety and Steady-State Pharmacokinetics of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12","primaryCompletion":"2013-10","completion":"2013-11","firstPosted":"2012-12-11","resultsPosted":"2015-05-21","lastUpdate":"2015-06-26"},"enrollment":160,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Placebo MDPI","otherNames":["Placebo Spiromax®"]},{"type":"DRUG","name":"Albuterol MDPI","otherNames":["ProAir® RespiClick, Albuterol Spiromax®"]}],"arms":[{"label":"Placebo MDPI","type":"PLACEBO_COMPARATOR"},{"label":"Albuterol MDPI","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of Albuterol Spiromax® versus placebo in subjects with persistent asthma.","primaryOutcome":{"measure":"Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period","timeFrame":"Day 1, Day 8 and Day 85","effectByArm":[{"arm":"Placebo MDPI","deltaMin":0.38,"sd":0.114},{"arm":"Albuterol MDPI","deltaMin":1.3,"sd":0.12}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":35,"countries":["United States"]},"refs":{"pmids":["26369589"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":75},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache"]}}